Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Inclusion Criteria: * Male or female patients age ≥ 18 years. * Known or suspected non-metastatic basal cell or squamous cell carcinomas ≥10 mm longest diameter or non-metastatic melanoma ≥6 mm longest diameter scheduled for excision, without advanced disease. * Written Informed Consent. * Agree to the use of effective contraceptive from Baseline and for 30 days after treatment if either male or female of child bearing potential. * Available for and able to comply with study requirements. Exclusion Criteria: * Women who are lactating/breastfeeding * Women with a positive pregnancy test or who are planning to become pregnant during the duration of the study. * Life expectancy \<6 months. * Karnofsky Performance Status of ≤70%. * The following laboratory abnormalities: * Neutrophil count \<1.5 x 10\^9/L * Platelets \<75 x 10\^9/L * Haemoglobin \<10 g/dL (may be determined following transfusion) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x upper limit of normal (ULN) * Total bilirubin \>2x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction) * International Normalized Ratio (INR) \>1.5 * Creatinine \>1.5x ULN * History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine and/or hospitalization. * Uncontrolled asthma or asthma requiring oral corticosteroids. * Clinically significant chronic inflammatory skin conditions, including psoriasis, atopic dermatitis and scleroderma, as determined by the investigator. * Unstable angina, myocardial infarction, known or suspected transient ischemic events or stroke within 24 weeks of Screening. * Uncontrolled hypertension. * QTc (corrected QT interval) prolongation \>450 msec. * Receipt of photosensitising drugs within 30 days of screening. * Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV). * Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data. * Known or suspected sensitivity to study product or excipients. * Prior participation in this clinical trial (has received study product).